less than 5cm liver cance
Conditions
Interventions
Control group:TACE by As2O3-PLGA microspheres
experimental group:TACE sequential with MWA
Sponsors
The First Affiliated Hospital of Zhengzhou University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. The diagnosis of hepatocellular carcinoma in patients is confirmed by histopathology, or qualify as the clinical diagnosis and staging criteria of primary liver cancer in China. Non-resectable or non-surgical HCC patients; According to the requirement of RECIST 1.1, it was required to measure the diameter of the spiral CT scan of the lesion with a diameter of more than 10mm or enlarged lymph node with a short diameter of 15mm. The maximum tumor is less than 5cm; No portal vein trunk completely blocked; 2. Tumor Stage: BCLC stage B - C stage; 3. male or female aged between 18 and 75 years old; 4. one week between accepted the ECOG PS scores: 0-1,KPS 60; 5. The percentage of liver tumor was 75% smaller than that of the whole liver, and the life expectancy was 3 months; 6. there are no serious complications, such as high blood pressure, coronary heart disease and history of mental illness,serious allergies; 7. The liver function should reach the child-pugh grade A or B, the renal function is normal, the coagulation function is normal or corrected after treatment; 8. HBV DNA < 2000 IU/ml (104 copies/ml); 9. Childbearing age Women shall undergo pregnancy test within 7 days prior to the entry of the group; 10. The patient signed the informed consent to participate in the experimental study; Can follow up, compliance is good.
Exclusion criteria
Exclusion criteria: Patients who meet the following 1 or several are not involved in this study 1. It has been known as hepatic cholangiocarcinoma and mixed cell carcinoma and fibroblastic cell carcinoma. In the past (5 years) or at the same time, there are other uncured malignancies, except for the treated skin basal cell carcinoma and cervical carcinoma in situ; Diagnosis of liver cancer but widespread metastasis; 2. In the four weeks prior to the study, any local treatment other than TACE was accepted; 3. Severe hepatocellular jaundice, liver failure, massive ascites, uncontrolled infection; 4. Severe heart, lung, kidney disease, severe uncorrected coagulant dysfunction; 5. In the past six months, there was a history of gastrointestinal bleeding or a clear tendency of gastrointestinal bleeding. During the 28 days before the study, abdominal fistula, gastrointestinal perforation or abdominal abscess occurred; 6. Pregnant or lactating patients; Patients with liver transplantation (except patients with previous liver transplantation); 7. The whole body is in decline, and the survival period is expected to be < 3 months; 8. The patient was unable to complete the treatment for various reasons and was unable to follow up in 3 months.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Overall Survival;Disease Control Rate, DCR;Time To Progress, TTP; | — |
Countries
China
Contacts
Public ContactHan Xinwei
The First Affiliated Hospital of Zhengzhou University
Outcome results
None listed